INDV Q2 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$302M+1.0% YoY

Gross Profit

$250M82.8% margin

Operating Income

$72M23.8% margin

Net Income

$18M6.0% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

$166M

Free Cash Flow

$148M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.7B

Stockholders' Equity

-$258M

Cash & Equivalents

$510M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$302M	$299M	+1.0%
Gross Profit	$250M	$220M	+13.6%
Operating Income	$72M	-$118M	+161.0%
Net Income	$18M	-$97M	+118.6%

Revenue Segments

Reportable Segment

$302M100%